CSwMR

Availability of Antimalarial Medicines and Commodities
Table 3.29 shows the availability of antimalarial medicines and commodities in
facilities offering malaria services.
At the national level, among the facilities providing services for malaria diagnosis
and/or treatment, the most widely available antimalarial medicines and commodities were
injectable quinine, found in 81 percent of cases, pediatric first-line ACT (artemisinin-based
combination therapy) in 60 percent of cases, sulfadoxine/pyrimethamine (SP) in 58 percent
of cases, and insecticide-treated bed nets (ITN) in 55 percent of facilities.
The availability of injectable quinine, the most often used antimalarial medicine, was
greater at health posts and health centers (respectively 81 percent and 84 percent) than at
hospitals (70 percent), and greater in the public sector than the private sector. At the regional
level, Kaffrine and Fatick had the highest availability (100 percent) and Dakar the lowest
percentage (61 percent).
In facilities providing services for malaria diagnosis and/or treatment, there was
limited availability of other antimalarials; non-artemisinin monotherapies were observed
most often—in 38 percent of facilities—followed by the first-line ACT antimalarials for
adolescents (16 percent), first-line ACT for adults (15 percent), injectable artesunate (3
percent), and oral quinine (2 percent).
50